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Abstract 
 
 
BACKGROUND:  With the strikingly longitudinal distribution of multiple sclerosis 
prevalence and incidence throughout the planet, it has been suggested that past sun 
exposure may be implicated in the development of MS.  Namely, vitamin D synthesized 
from sun exposure has been the main focus of this burgeoning area of research.  It has 
been hypothesized that low levels of vitamin D increase the risk of developing multiple 
sclerosis.  
METHODS:  A systematic review of the most current literature pertaining to vitamin D 
and the development and pathology of MS was performed using MEDLINE-Ovid, All 
EBM Reviews and CINAHL.  Search terms utilized were “vitamin D” and “multiple 
sclerosis” combined with the “and” command.  A modified validity score (0-9) was 
assigned to the articles in order to objectively measure the validity of the overall results 
of each paper.   
RESULTS:  Nine studies met inclusion criteria, and were subsequently utilized in the 
review.  Four studies were case-control type, three were cross-sectional studies and two 
were large cohorts.   
CONCLUSION:  Based on this systematic review, it appears that there is an inverse 
relationship between circulating vitamin D levels and risk of developing multiple 
sclerosis.  Moreover, it appears that vitamin D not only acts as a disease determinant, but 
also a disease modifier, as is evidenced by its correlation with relapses and in its newly 
discovered specific immunomodulatory properties. 
KEYWORDS:  vitamin D; multiple sclerosis 
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Introduction 
 
  
Multiple sclerosis (MS) is a fairly common disorder which is classified as a 
demyelinating disease of the central nervous system.  It affects women more frequently 
than men, with a male to female ratio of nearly 1:4.  In total, MS affects around 350,000 
United States citizens and an estimated 2.5 million people worldwide.  The age of onset 
ranges from 20 – 40, with a peak near 30.  It is classified as either relapsing-remitting, 
primary progressive, secondary progressive or primary-relapsing.  Relapsing-remitting is 
by far the most common (affecting 85% of the MS population) and, as the name implies, 
it is the mildest form which is characterized by periods of exacerbation and remission.    
Frustrating both clinicians and patients alike, is the fact that the pathogenesis of 
MS is still not completely understood.   Moreover, recent research has uncovered 
evidence that seems to suggest that each subtype may be a result of a slightly different, 
and distinct, disease process.3 This fact only serves to further complicate the issue of 
understanding the pathology and subsequent treatment of MS.  What is known, however, 
is that multiple sclerosis seems to result from a number of different factors, including 
genetic susceptibility, history of Epstein-Barr virus (EBV) infection, environmental 
factors1and ultimately a continued dysfunctional immune response.  This being said, MS 
can be generally viewed as an autoimmune condition whereby T cells attack specific 
myelin bands in the central nervous system.9 Multiple plaques may been seen on an MRI 
of the brain, where the white matter is being attacked by CD4+ T cells, and a host of 
monocytes and macrophages.   
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Despite the possible differences in etiologies, each subtype can produce a 
multitude of similar symptoms that can be highly debilitating to the patient.  Some of the 
most common include generalized weakness, blurred vision, muscle spasticity, 
paresthesias in a non-dermatomal pattern, impaired coordination, ataxia, bladder 
dysfunction, bowel dysfunction and sensitivity to heat.  These symptoms, among others, 
may come and go (as in relapsing-remitting MS), or begin and persist throughout the 
disease course (as in primary progressive MS).    
What is very striking is that the incidence of multiple sclerosis at the equator is 
nearly zero, while the incidence in the United States, collectively, is around 1:1000.6 In 
fact, it is not only the U.S. that suffers such a high incidence of this central nervous 
system disorder, but all countries throughout the world at latitudes roughly equal to the 
U.S.  More specifically, there appears to be a gradual increase in incidence and 
prevalence of all types of MS as the north and south poles are approached from the 
equator.14 This pattern is quite consistent throughout the entire planet; with increasing 
latitude comes increasing risk of developing MS.  With this observation in place, it has 
been asserted that perhaps reduced exposure to sunlight is an important environmental 
factor in the development of multiple sclerosis.   
With sunlight being implicated in the development of multiple sclerosis, naturally 
Vitamin D follows.  This is because the vast majority of vitamin D is not acquired 
through dietary means, but synthesized by the skin secondary to ultraviolet radiation from 
the sun.  In fact, full body exposure to the peak summer sun for 10-15 minutes will 
synthesize and release about 20,000 units of vitamin D3, or about 50 times the 
recommended daily dose.14 Specifically, it is the UVB rays that cause the skin to generate 
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Vitamin D3 from 7-dehydrocholesterol.17 There exists an ample amount of 7-
dehydrocholesterol in the stratum basale layer of the hypodermis, where it is 
endogenously produced.  It is this stockpile of vitamin D3 precursor, that is readily 
converted to pre-vitamin D3 when exposed to sunlight.  Pre-vitamin D3 is then converted 
to vitamin D3 (cholecalciferol), which is the form most often taken in dietary 
supplements.  It is this form that is then converted, by the liver, to the first of two 
principle metabolites found in the human body; 25(OH) vitamin D (calcidiol).  It is 
calcidiol that is often measured to assess for vitamin D deficiency, despite the fact that it 
is not regarded as the biologically active form of vitamin D.  The product of calcidiol 
hydroxylation (via 1α-hydroxylase) by the kidneys is the second principle metabolite, and 
the biologically active form of vitamin D; 1,25(OH)2 vitamin D (calcitriol).13   
Vitamin D is most widely known as a regulator of calcium absorption and 
subsequent utilization by facilitating the absorption of dietary calcium, and is therefore 
linked to osteoporosis and osteopenia.  In recent years it has been proven to also have 
immunomodulatory properties, some of which are just being discovered.2-3,7 Vitamin D 
deficiency has been linked to many disease processes including MS.  What is still 
unknown is exactly how vitamin D is involved in the pathogenesis of these diseases, if at 
all, for, simple correlation does not necessarily equal causation. 
It is the aim of this study to investigate the correlation between vitamin D 
deficiency and multiple sclerosis.  Furthermore, an effort will be made to uncover any 
causality which may exist between the lack of vitamin D and the development and 
severity of MS.  In order to accomplish this, and to address to the hypothesis, focus will 
be placed on the most recent, pertinent, literature available. 
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It is the hypothesis of this paper that there exists a significant inverse relationship 
between vitamin D levels and the risk of developing MS.  Moreover, the active role 
played by vitamin D in immune system modulation possesses significance in multiple 
sclerosis pathology. 
The implications of this possible link between vitamin D and multiple sclerosis 
could be very important.  With such a high proportion of the world’s population being 
affected, no definitive cure and only mildly effective symptomatic treatments, it would be 
a monumental advancement if a link were to be discovered and later developed into a 
new form of prevention and even treatment.  If it were as simple as high dose vitamin D 
replacement, it would be supremely cost effective and available to nearly every MS 
patient worldwide.  It could decrease the current MS burden markedly, and possibly 
eliminate multiple sclerosis in future generations. 
 
 
Methods 
 
In order to gather all of the most pertinent articles relating to the chosen topic, an 
exhaustive literature search was undertaken making use of MEDLINE-Ovid, CINAHL, 
and All EBM Reviews.  The search terms utilized were, “Vitamin D” and “Multiple 
Sclerosis.”  These terms were searched separately as keywords, then combined to form a 
single search using the “and” command.  The literature search for articles was limited to 
the English language, human populations and must have been published between 2004 
and 2009.  Furthermore, systematic reviews were excluded along with meta-analyses.  
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After narrowing the search as described, articles were further investigated and excluded if 
they did not directly address the interaction between vitamin D and the development and 
pathology of multiple sclerosis.   
There appeared to be two distinct types of articles remaining after further 
narrowing the search in this manner.  First were articles which focused on the risk of 
developing MS as associated with vitamin D deficiency, and examined the possible 
pathological explanation, and second were those assessing the use of vitamin D as a 
treatment in patients with established MS.  While the latter are of great interest and 
relevance to MS research, they addressed a slightly different topic with a much different 
PICO (population, intervention, comparison and outcome) than the former, and were 
subsequently excluded.   
The remaining articles were then critically appraised and assessed as to their 
validity and reliability in relation to the clinical question.  The Jadad score, which is a 
commonly used set of criteria to assess the validity of certain types of articles, could not 
be applied to the remaining population of works, as they were not randomized controlled 
trials.  It became necessary to create a new validity grading scale, to more formally assess 
the group of articles accrued.  This modified validity scale (MVS) can be viewed in 
appendix A.  Each article was given a numeric score according to this set of criteria.  This 
score, ranging from 0-9, would then represent how much weight should be given to the 
article in supporting the hypothesis. 
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Results 
 
In all, nine studies met inclusion criteria.  Furthermore, all nine were 
homogeneous enough to allow for comparison between them where appropriate.  Four of 
the studies were case-control type, two were large cohorts and three were cross-sectional 
type studies.  In compliance with inclusion criteria, the studies were limited to the last 
five years, and all focused on vitamin D deficiency as it relates to the risk of developing 
multiple sclerosis.  Some went on to investigate the possible immunological link between 
vitamin D and the pathological processes of MS.  Collectively, the studies demonstrated 
an increased risk for the development of MS with deficient levels of vitamin D.  Those 
which investigated the role of vitamin D in the immunological response with regard to 
MS, showed a significant correlation between vitamin D and clinical disease activity, and 
one even touched on specific cellular interactions within the immune system.   
The case-control study, Immunomodulatory effects of Vitamin D in multiple 
sclerosis (2009), investigated not only the relationship between vitamin D levels and 
multiple sclerosis, but went on to explore the specific immunomodulatory effects of 
vitamin D on the human body.  The investigators began by selecting 132 Hispanic 
patients with diagnosed MS and subdividing them into three separate groups: relapsing-
remitting multiple sclerosis (RRMS) in remission, relapsing-remitting multiple sclerosis 
(RRMS) in acute exacerbation, and primary progressive multiple sclerosis (PPMS).  They 
then selected 60 healthy control subjects from the same geographical location (Buenos 
Aires, latitude 34.5°, longitude 58°) and matched them to experimental groups with 
respect to race, age, place of residence and gender.  The control group was also 
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subdivided into two separate groups which differed only in age.  This was done to better 
match for age between the relapsing-remitting and the primary progressive groups.  As is 
the case in the general MS population, patients in this study who suffered from PPMS 
were significantly older than those with RRMS. 
The researchers began by measuring 25(OH) vitamin D and 1,25(OH)2 vitamin D 
levels in each of the participants.  They found that both 25(OH) vitamin D and 1,25(OH) 
2 vitamin D levels were significantly lower in relapsing-remitting subjects during both 
remission and acute exacerbation when compared to the control groups.  Moreover, they 
found significantly lower levels of both vitamin D metabolites in patients during 
exacerbation than when in remission.  However, they found no significant difference 
when comparing vitamin D levels of primary progressive MS patients with healthy 
controls.  Overall, these results indicated to the researchers that both forms of vitamin D 
are significantly lower in RRMS, particularly during an acute exacerbation.  They also 
provide some evidence toward the growing hypothesis that PPMS and RRMS are of two 
distinct pathologies, being that vitamin D levels in PPMS did not differ from healthy 
controls. 
The authors then cultured peripheral blood mononuclear cells (PBMC) taken from 
both control and experimental groups.  They grew out CD4+ T cells ex vivo, as well as 
dendritic cells to mimic the myelinated cells which are attacked in MS.  They were able 
to then introduce 1,25(OH) 2 vitamin D to the cultured cells and compare the results to 
controls using 25,26(OH) vitamin D and 24,25(OH) vitamin D.  They found that CD 4+ 
cells and MBP-peptide specific T cell proliferation was inhibited by 1,25(OH) 2 vitamin 
D, but not by the two vitamin D controls.  The percentage of inhibition was found to be 
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dependent on the concentration; higher concentrations equaled greater inhibition.  
Furthermore, this inhibition was consistent between MS and control groups. 
The scientists were also able to investigate T cell conversion of 25(OH) vitamin D 
to 1,25(OH) 2 vitamin D in the periphery.  It has recently been shown that the 
hydroxylation of calcidiol not only occurs in the kidneys, but also in different tissues 
throughout the body, via 1α-hydroxylase.  The authors studied this by looking at 
expression of 1α-hydroxylase mRNA by CD4+ T cells, which were found to 
constitutively express this mRNA while in a resting state, and were also significantly up-
regulated when activated.  They also found that the addition of [3H]-25(OH) vitamin D 
was converted to [3H]-1,25(OH)2 vitamin D with a significant rise in 1α-hydroxylase 
activity (8-10 fold after 24 hours of incubation, and 25-33 fold after 48 hours).  
Collectively, this demonstrated that CD4+ T cells were capable of metabolizing calcidiol 
to calcitriol, and as a result, would inhibit CD4+ T cell proliferation due to the increased 
levels of calcitriol. 
The authors went on to investigate the effect of vitamin D on T cell function.  To 
accomplish this, they looked at the products of T cells; cytokines.  They looked at IFN-γ, 
IL-4, IL-6, IL-10 and IL-17 to assess T cell function in the absence and presence of 
calcitriol in both control, and MS cell lines.  What they found was that the calcitriol led to 
decreased numbers of IL-6 and IL-17 producing T cells, and an increase in IL-10 
producing T cells in both control and MS groups.  This particular experiment confirmed 
the fact that IL-10 is a positive autocrine factor that acts directly on the T cells and 
enhances the action of calcitriol, thereby creating a type of positive feedback loop.  It was 
also demonstrated that there was a down regulation in IL-17 and IL-6, which is of great 
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importance because IL-6 has been shown to be a critical factor in Th17 production, which 
is thought to be a important T helper cell, responsible for tissue injury in autoimmune 
disease.  
To further understand the immunological role of vitamin D, the team examined 
IDO (indoleamine 2,3, dioxygenase) mediated tryptophan catabolism in relation to 
CD4+CD25+ FoxP3+ T cells.    What they found was that both CD4+ T cells and 
dendritic cells of MS patients and controls displayed IDO mRNA presence, and that these 
levels were significantly increased after exposure to 1,25(OH)2 vitamin D.  Furthermore, 
the calcitriol significantly increased CD4+CD25+FoxP3+ regulatory T cell percentages.   
Overall, this study found those with RRMS to have significantly lower vitamin D 
levels than matched controls.  Moreover, levels were lower during exacerbation of 
RRMS.  They also found that in PPMS, vitamin D levels were the same as matched 
controls.  They went on to find a body of evidence suggesting that vitamin D, specifically 
the 1,25(OH)2 vitamin D metabolite, is an integral part of the immunomodulatory system. 
In 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis (2005), 
the authors evaluated vitamin D levels in newly diagnosed MS patients, and compared 
them to healthy controls.  The controls were not matched for age, sex or race.  Serum 
vitamin D levels were drawn in all patients in the same manner and processed using the 
same equipment.  It was found was that there was no difference between controls and MS 
patients with regards to vitamin D levels, except in the summer months, when there was a 
statistically significant difference.  MS patients suffered from vitamin D deficiency in the 
summer, while controls did not.  Furthermore, the scientists noted a significant difference 
in vitamin D levels between MS patients whose blood was drawn during a period of 
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remission versus those who were experiencing a relapse.  Patients in relapse at the time of 
vitamin D assessment were found to be significantly lower in circulating vitamin D than 
the MS patients who were in remission.  
In Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis (2006), the 
investigators made use of a prospective, nested, case-control study.  It was their sole aim 
to assess whether or not 25(OH) vitamin D levels were associated with the risk of 
developing MS.  They made use of a population of 7 million U.S. military personnel who 
had serum samples stored with the Department of Defense Serum Repository.  They 
identified 257 MS cases diagnosed between1992 and 2004 which were then included in 
the study.  Each MS case was assigned two controls which were matched by age, sex, 
race and dates of blood collection.  The results of their analysis showed an overall 
significant trend of increasing risk for MS with decreasing 25(OH) vitamin D levels for 
Caucasians.  In fact, with each 50-nmol increase in serum vitamin D levels, there was a 
41% risk reduction.  However, this was found to be race specific, among African-
Americans and Hispanics, there was not a significant trend. 
Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 
concentrations in male and female multiple sclerosis patients and control volunteers 
(2007) also investigated the possible link between the two major vitamin D metabolites 
and multiple sclerosis.  Specifically, this group sought to uncover whether or not 
1,25(OH)2 vitamin D was correlated with MS development and its clinical activity.  In 
this cross-sectional study, 29 MS patients were compared with 22 age and sex matched, 
healthy control subjects.  Serum samples were drawn and tested for both vitamin D 
metabolites, as well as parathyroid hormone (PTH).  They found no significant 
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differences between MS patients and controls with regard to vitamin D levels and PTH.  
They did note a significantly higher vitamin D level in women as a whole when 
compared to men as a whole, despite finding no significant difference between MS 
women and control women.  This led them to conclude that there may be different 
vitamin D requirements as it pertains to sex.     
 In Vitamin D levels in people with multiple sclerosis and community controls in 
Tasmania, Australia (2005), the researchers recruited MS patients from Tasmania, as 
well as controls.  In total, there were 136 MS patients, and 272 controls matched for age 
and sex in this cross-sectional, case-control study.  Not only did they measure vitamin D 
via serum samples, but they also measured approximate sun exposure time using a “time 
in sun” survey questionnaire.  They also matched this subjective information with 
objective signs of sun exposure by obtaining silicon casts of subjects’ hands and 
inspecting for actinic damage.  Furthermore, they utilized a spectrophotometer on the 
upper inner arm and buttock to assess skin phenotype, and measured the average intake 
of vitamin D through dietary means using a specific questionnaire geared towards 
vitamin D.   
 In combining these factors, they were able to show that disability level in MS was 
strongly associated with lower 25(OH) vitamin D levels as well as reduced sun exposure.  
Cases with a higher disability score (EDSS) were more likely to have vitamin D 
insufficiency than matched controls.     
 The authors of Higher levels of 25-hydroxyvitamin D are associated with a lower 
incidence of multiple sclerosis only in women sought to study the role of vitamin D 
metabolism in MS.  They utilized two blood samples (summer and winter) from 103 MS 
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patients and 110 healthy control subjects to assess calcidiol and calcitriol levels.  They 
found that both the control group and the experimental group had significantly higher 
levels of both vitamin D metabolites in the summer months versus the winter months.  
They also found that there seemed to be a link between MS and 25(OH) vitamin D levels, 
but only in women.  They calculated a reduction in MS risk of 19% for every 10-nmol/L 
rise in serum 25(OH) vitamin D levels.  Furthermore, they found a significant correlation 
between winter serum vitamin D levels and summer EDSS scores.  This suggested to the 
researchers that the lower serum vitamin D levels in the winter months caused the higher 
disability scores (EDSS) in the summer.  They attributed the inverse relationship of 
EDSS score and vitamin D levels to lag time in vitamin D uptake, metabolism and effect 
on the immune system.  However, this relationship was found only in women, which led 
the researchers to conclude that the protective effect of 25(OH) vitamin D was exclusive 
to women. 
 In a large prospective cohort study of female nurses, Vitamin D intake and 
incidence of multiple sclerosis (2004), the designers made use of a very large number of 
women to investigate the link between vitamin D and MS.  In fact, two cohorts were used 
to select study subjects.  They were the Nurses’ Health Study, comprised or 92,253 
women, and the Nurses’ Health Study II, made up of 95,310 women.  The original NHS 
followed women from 1980 to 2000, and the NHS II followed the participants from 1991 
to 2001.  In total, 173 cases of MS were diagnosed during the study timeframe, which 
were then used for comparison to healthy controls.  The study designers not only 
measured vitamin D intake from diet, but a multitude of other nutrients, as well as other 
possibly relevant pieces of information such as smoking history and latitude of 
21 
 
birthplace.  Of course, in addition to the above, serum vitamin D levels were measured.  
With all the information in place, they were able to construct quintiles in regards to total 
vitamin D intake.  What they found was that the total vitamin D intake, at baseline, was 
inversely correlated with risk of MS.  In comparing the lowest quintile to the highest 
quintile, there was a risk redution of 0.67 in regards to developing multiple sclerosis, 
resulting in a finding that women who used supplemental vitamin D (which came largely 
from multi-vitamins) had a 40% lower risk of developing MS than women who did not. 
 M Soilu-Hanninen and his colleagues investigated the role of vitamin D in MS in 
the paper, A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid 
hormone levels indicate the importance of vitamin D and calcium homeostasis regulation 
in multiple sclerosis (2008).  In it, the correlation between vitamin D metabolism and MS 
activity was studied.  In order to accomplish this, they measured 25(OH) vitamin D, PTH, 
calcium, phosphate, magnesium, chloride, alkaline phosphatase, albumin and TSH in 23 
patients with MS, and 23 healthy controls.  These samples were obtained via 
venipuncture at three month intervals for one year, and at times of clinically defined 
relapse in the patients with multiple sclerosis.  To further assess multiple sclerosis 
progression, and the possible correlation between it and vitamin D levels, the group also 
observed the demyelinating lesions secondary to MS, by utilizing MRI of the brain 
during periods of relapse. 
 What they discovered was that vitamin D deficiency was common in both groups, 
(affecting approximately half of the controls and MS patients sometime during the year) 
but that 25(OH) vitamin D serum levels were significantly lower, and PTH levels 
significantly higher, in the MS group during acute exacerbations when compared to 
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periods of remission.  They found that in each case of relapse, the PTH was greater than 
20 ng/L, and may have actually been a more reliable marker for MS relapse than 25(OH) 
vitamin D.  With the correlation between low calcidiol and increased MS clinical activity 
in place, as well as no appreciable difference between controls and MS groups with 
regard to overall vitamin D levels, the authors suggested that vitamin D may actually be 
functioning as a disease modifier in multiple sclerosis patients, rather than just a disease 
determinant in the general population.  They go on to admit that this relationship has one 
of two explanations: either higher levels of circulating vitamin D reduce the risk of MS 
exacerbation, or multiple sclerosis relapse reduces serum vitamin D levels.  However, the 
team goes on to state that they found a trend, which did not reach significance, (possibly 
secondary to the small population of participants) showing a correlation between 
increasing 25(OH) vitamin D levels and lower incidence of relapse, as well as less EDSS 
progression.  This trend, though not statistically significant, reinforces their hypothesis 
that higher calcidiol levels reduce the risk of MS relapse, rather than MS relapse 
depleting vitamin D levels.  They felt able to reach this conclusion despite the fact that 
there seemed to be no correlation between vitamin D levels and MRI parameters for 
relapse. 
 In the cross-sectional study, Association of vitamin D metabolite levels with 
relapse rate and disability in multiple sclerosis (2008), J Smolders and his fellow 
investigators aimed to explore the possible link between low circulating serum levels of 
calcitriol and calcidiol and increased disability and severity of MS.  The researchers 
recruited 267 patients with confirmed multiple sclerosis, further identifying them as 
relapsing-remitting, primary progressive, secondary progressive or unknown.  Each was 
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enrolled from the University Hospital outpatient clinic from 2005-2007 and lived in the 
southern area of the Netherlands (latitude 50-51°).  The study did not make use of 
matched, healthy controls, but instead compared each MS subgroup to each other, as well 
as to assigned “normal” vitamin D levels.  The investigators measured both 25(OH) 
vitamin D and 1,25(OH)2 vitamin D levels a single time in each study volunteer.  They 
also monitored MS clinical activity (number of relapses and overall disability levels) 
using the EDSS scoring criteria, and then calculated a one-year relapse rate for each 
subject. 
 Overall, the results of the study showed that circulating levels of both vitamin D 
metabolites were significantly lower in the progressive forms of MS when compared to 
RRMS.    Furthermore, they found no significant association between vitamin D 
metabolites and relapse rate.  However, when comparing RRMS patients who suffered 
relapses to those who did not, the relative risk of remaining relapse free in the previous 
two years increased by 51% for each 10 nmol/L increase of 25(OH) vitamin D.  They 
also noted that both vitamin D metabolites were lower in patients with one or more 
relapses than those without any relapses.  What also surfaced was the fact that high levels 
of both calcidiol and calcitriol were associated with a high chance of remaining relapse 
free.  As a consequence, it was concluded that the raw 25(OH) vitamin D levels 
correlated negatively with EDSS scores in the entire study population. 
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Discussion 
  
When taken together, the evidence from each of the above articles is striking.  It 
suggests that vitamin D plays an integral role in multiple sclerosis development and 
pathology.  With the exception of one article, (Assessment of 25-hydroxyvitamin D and 
1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients 
and control volunteers) all of the research demonstrated a significant link between 
vitamin D and either the development, pathology or both, of multiple sclerosis.  Not only 
does it seem to be “protective,” (or preventative) as has been asserted previously,2 but it 
seems to have an active, and helpful, role in the dysfunctional immunologic response of 
multiple sclerosis.3 
Each of the articles (except the Barnes study) outlined the benefit of higher 
circulating levels of vitamin D, and many highlighted a link between relapse and lower 
levels of vitamin D, thereby reinforcing the presumed correlation between vitamin D and 
the pathological process of MS.  Immunomodulatory effects of Vitamin D in multiple 
sclerosis (2009) supplied detailed evidence to further support a link between vitamin D 
and MS.  The authors of this paper went into depth in exploring not simply the 
correlation, but the specific immunological and biochemical reactions that are a direct 
result of the presence of vitamin D.  They were then able to hypothesize why vitamin D 
levels were correlated to relapses in, and the pathogenesis of MS.   
In a series of experiments, Correale and his colleagues demonstrated that 1,25 
(OH)2 vitamin D exerts its immunomodulatory effects on the immune system.  By adding 
vitamin D to T cells from participants, they were able to demonstrate the inhibition of 
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CD4+ T cells, as well as local conversion of 25 (OH) vitamin D into 1,25 (OH)2 vitamin 
D by the T cells themselves.  They were also able to show that production of certain 
cytokines was significantly altered by addition of calcitriol.  IL-10 was increased, which 
solidified its role as a positive autocrine factor; a regulator of the immune system.  IL-6 
and IL-17 production was significantly decreased in response to calcitriol.  This is of 
great importance because IL-6 is a critical factor in the production of Th17, which is an 
important cell type in the autoimmune response, specifically, one responsible for tissue 
destruction.   If IL-6 is down-regulated by 1,25(OH)2 vitamin D, then Th17 should also 
be down-regulated as a consequence.  In turn, this could result in a decrease in tissue 
damage, which may manifest as a decrease in MS relapse rate and disability.   
The team went on to investigate the activity of calcitriol on tryptophan 
metabolism in CD4+CD25+ FoxP3+ T cells.  It has been previously shown that the IDO 
induced tryptophan catabolism suppresses T cell responses, and promotes tolerance in 
autoimmune, pregnancy and allergic mediated inflammation.11,16 Simply stated, it 
dampens the immune response, which could be potentially important in multiple sclerosis 
treatment.  By demonstrating that mRNA of IDO was significantly increased after 
addition of calcitriol, the researchers compiled further evidence that vitamin D is an 
important immunomodulator.  It directly, and significantly, increased the presence of 
IDO mRNA in CD4+CD25+ FoxP3+ T cells, which have been shown to be vital in the 
inhibition of autoimmune diseases and graft rejection (specifically CD4+ and CD25+ T 
cells). 
With the exception of the 2007 M.S. Barnes study, all the articles supported the 
hypothesis presented by this paper.  The discordant results of the Barnes study may be 
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due to a number of factors.  First, the study made use of a small sample size (29 MS 
patients and 22 controls), which decreases the power of the article and makes attainment 
of statistical significance between values very difficult.  Furthermore, the design itself 
may have led to its divergence from the other articles.  The cross-sectional study design 
only incorporated a single vitamin D level for each study participant.  Moreover, the 
sample was taken in late February through early March, which according to a previous 
study,14 is a point in time where there may be no notable difference between controls and 
MS patients in regards to vitamin D levels.  This same study demonstrated that, while 
vitamin D status did not differ in the winter months, it was significantly different in the 
summer months.  Furthermore, it found statistically significant differences in vitamin D 
levels when comparing MS patients in remission with those experiencing a relapse.  The 
Barnes article did not assess either of these two variables, which may have led to the 
eventual incongruent conclusion. 
There was no incongruence, however, between articles that investigated vitamin 
D levels at times of relapse or remission.  Each study found that, during an acute 
exacerbation of RRMS, there were significantly lower levels of vitamin D.  The 2008 M 
Soilu-Hanninen paper went so far as to try to prove, qualitatively, that it was not the 
disease activity causing the vitamin D stores to be low, but rather the low levels of 
vitamin D causing the relapse.  They concluded that, in fact, that this was the case.  It was 
in this indirect fashion that the authors were able to provide more evidence that vitamin D 
is an active immunological molecule that functions in the MS disease process.  Not only 
might the vitamin D metabolites, specifically 1,25(OH)2 vitamin D, be an important 
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immunomodulator in the primary prevention of MS, but also in the prevention of relapse 
and progression as well.   
Another inconsistency worth noting in the articles reviewed can be found within 
the 2009 article by JJ Kragt.  They found that higher levels of 25(OH) vitamin D were 
associated with a lower risk of MS, but only in women.  This is not in agreement with the 
remainder of the articles reviewed.  The explanation might be found in the design of the 
study, particularly in the control group.  First, the selection of the control group was far 
from random, “Patients were asked to bring a healthy control with them when possible, 
preferably their partner because this would result in roughly matching for age and 
simultaneous enrollment of patients and controls.”  When a control was not included in 
the study by the MS patient referral, a hospital employee volunteer was taken.  This 
method of control group recruitment is far from random, and therefore negatively 
impacted the validity of the study.  Furthermore, it has been shown that it is necessary to 
match controls for age, place of residence and especially sex, (as the rest of the studies 
reviewed did) for these factors will change the vitamin D levels in normal, healthy adults.  
This study did not match for sex, in fact, in its ideal design, each MS patient would bring 
in their partner, which would be of the opposite sex nearly 100% of the time.  Moreover, 
the effect of this poorly selected control group can be seen in their Table 1, where it 
shows a statistically significant difference between the control and MS groups with 
regards to sex (p value = 0.001) at the onset of the study.  This alone could account for 
their results which were inconsistent with those of the other articles reviewed.  However, 
this anomaly was not the only statistically significant difference between controls and MS 
patients at the beginning of the study.  There was also a significant difference in regards 
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to the use of supplements containing vitamin D, and a significant difference with regards 
to birthplace.  Both of these factors are well known determinants for both vitamin D 
status 5,18 and risk of MS.    
When taken together, the faulty design by which controls were recruited, as well 
as the resultant significant differences between the control group and the multiple 
sclerosis group detract from the validity of the study’s results.  If the control and MS 
groups had not been significantly different, especially in regards to sex, one would be 
able to accept the results with more confidence.  But as it stands, one must be highly 
skeptical of the conclusion drawn by the authors of this article, especially in light of the 
other literature which contradicts it. 
The limitations of this systematic review are those placed upon it by the review 
articles themselves.  The quality and quantity of the papers which make up a review 
article are of the utmost importance, and in this case, were of an acceptable quality.  With 
minor exceptions, each article was performed in such a way that allowed for a respectable 
validity score as shown in table II, which consequently adds to the validity and reliability 
of this review article.  However, what must be taken into account is that this MVS has not 
been analyzed to assess its own validity in rating research articles as the Jadad score has.   
While there was enough high quality, focused literature related to this paper’s 
hypothesis, there cannot be a definitive conclusion drawn as it relates to vitamin D in the 
treatment of MS.  Though it seems that vitamin D is implicated in the pathology, and 
pathogenesis of MS, the papers reviewed in this article did not address the issue of 
vitamin D as a treatment for multiple sclerosis.  Therefore, conclusions drawn from this 
paper must be limited to the role of vitamin D in the pathogenesis and immunological 
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response in multiple sclerosis.  There are a small number of articles in the literature 
which focus on the treatment of MS using vitamin D, though they did not meet the 
inclusion criteria. 
An animal study performed at the UW-Madison using EAE, (an animal model for 
MS) displayed the most powerful evidence yet for vitamin D.   Specifically, 1,25(OH)2 
vitamin D was shown to prevent the EAE from causing paralytic symptoms in mice when 
given before inoculation with the disease.  Furthermore, given after infection with EAE, 
1,25(OH)2 vitamin D was able to slow and stop the progression of paralysis when 
compared to controls.  What must be taken into account, of course, is the fact that this 
was an animal study, and may not translate similarly in a human model.  In humans, the 
studies using vitamin D as a treatment have only, thus far, focused on its general safety 
and efficacy in raising vitamin D levels, but have failed to place any focus on vitamin D’s 
effect on multiple sclerosis disease progression.  
 
 
Conclusion 
 
 Despite the small, but growing, number of articles available that evaluate the 
efficacy and safety of vitamin D treatment for multiple sclerosis,4-5,18 there is no current 
human study published that demonstrates the efficacy of vitamin D treatment for MS in 
reducing or preventing relapses or disease progression.  The possible ramifications of 
research of this type could be drastic.  There is a fair amount of literature currently 
available (much of it within the last decade) that addresses the very question posed by 
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this paper.  It first must be understood what role, if any, vitamin D plays in the pathology 
of multiple sclerosis before it can be used as a treatment.       
The medical community, as of late, has recently begun to acknowledge the 
importance of vitamin D deficiency for a variety of reasons.  A continually growing 
number of clinicians are measuring vitamin D levels, as it is the most common vitamin 
deficiency in the United States.  With this rise in awareness it seems reasonable to 
assume that more research will continue to surface with respect to treatment of multiple 
sclerosis with vitamin D.  
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Tables 
 
 
  
Table I: 
Pertinent Data 
    
Author & Year Population 
 
Outcome Comparison MVS 
I.A.F. van der 
Mei et al.  (2007) 
Patients <60 with 
diagnosed MS  
Increasing EDSS was inversely 
associated with vitamin D levles 
Unaffected, in the 
same area, 
matched for sex 
and age 
7/9 
M Soilu-
Hanninen et al.  
(2008) 
Patients diagnosed 
by both clinical and 
MRI findings. 
There is an inverse relationship 
between 25(OH) D and MS clinical 
activity (relapse vs. remission) 
Unaffected people 
living in the same 
area  
5/9 
Jorge Correale et 
al.  (2009) 
 
 
 
Patients with RRMS 
and PPMS 
MS population had lower 1,25 D 
and 25 D than controls; levels were 
lower during relapse than during 
remission; 1,25(OH)2 D acted as an 
immunomodulator  
Unaffected age 
and sex matched 
people from the 
same 
geographical area  
6/9 
K.L Munger et 
al.  (2004) 
cohort of female 
nurses who were MS 
free at the beginning 
of the study. 
Those women with higher Vitamin 
D levels had about a 40% less 
chance in developing MS. 
The unaffected in 
the cohort served 
as controls 
6/9 
Kragt JJ et al. 
(2009) 
Affected MS 
patients and 
unmatched controls 
Inverse relationship between 25 
vitamin D and MS, only in women, 
not men 
Unaffected 
volunteer 
5/9 
J Smolders et al.  
(2008) 
MS patients with 
RRMS SPMS and 
PPMS 
Serum 25(OH) D levels were 
associated, inversely, with both 
relapse rate and disability in MS 
patients 
Comparison 
between MS 
groups 
5/9 
Munger 
Kassandra L et 
al.  (2006) 
cohort of military 
personnel, MS free 
at time of enrollment  
Inverse relationship between 
vitamin D levels and MS 
development 
Unaffected 
personnel in the 
database  
9/9 
Barnes MS et al. 
(2007) 
29 patients with 
diagnosed MS 
They found that in women with 
MS, vitamin D levels were higher. 
Unaffected age 
and sex matched  
4/9 
Soilu-Hanninen 
M et al (2005)  
40 MS patients at 
the time of diagnosis 
Differences in D only in summer;  
difference between RRMS patients 
in relapse vs. remission 
26 non-MS pts. 5/9 
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Table II: 
MVS 
Barnes 
et al 
M Soilu-
Hanninen 
et al 
(2005) 
JJ 
Kragt 
et al 
 
Munger 
et al 
(2004) 
IAF 
van 
der 
Mei 
et 
al 
J Smolders 
et al 
Munger 
et al 
(2006) 
M Soilu-
Hanninen 
et al 
(2008) 
Cor- 
reale 
et al 
Sample size of 
at least 100? 
0 0 1 1 1 1 1 0 1 
Well defined 
inclusion criteria 
for MS? 
0 1 1 1 1 1 1 1 1 
Acceptable 
control subjects? 
(matched for 
age, sex 
residence, race) 
1 1 0 1 1 0 1 1 1 
Subjects similar 
at the beginning 
of the study?  If 
not, accounted 
for in somehow? 
1 1 0 1 1 0 1 1 1 
Outside forms 
of vitamin D 
accounted for? 
1 0 1 1 1 1 1 0 0 
Researchers 
blinded to 
control vs MS 
patients? 
0 0 0 0 0 0 1 0 0 
Reliable, 
repeatable 
measure of 
vitamin D? 
1 1 1 0 1 1 1 1 1 
Controls 
selected in a 
randomized 
fashion? 
0 0 0 0 1 0 1 0 0 
At least two 
vitamin D levels 
drawn? 
0 1 1 1 0 1 1 1 1 
Total 4 5 5 6 7 5 9 5 6 
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Appendix 
 
Appendix A:  Sample of MVS criteria 
Criteria Allowable Points Points Given 
Sample size of at least 100 
subjects? 
1  
Well defined inclusion criteria 
for multiple sclerosis? 
1  
Were there acceptable control 
subjects? (appropriately 
matched for age, sex, race and 
geographical site) 
1  
Were the subjects similar at 
the beginning of the study?  If 
not, was this accounted for in 
some way? 
1  
Were outside forms of vitamin 
D level interference cited and 
accounted for?  (dietary 
Vitamin D, time spent in sun, 
etc.) 
 
 
1 
 
Were researchers blinded to 
controls versus MS patients? 
1  
Reliable and repeatable 
measure of Vitamin D? 
1  
Were controls initially 
selected in a randomized 
fashion? 
1  
At least two vitamin D levels 
drawn? 
1  
